Pwrm,sppi,siga- Pennytobuck.com Stock Report
POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)
Last: $0.0375
Volume:258,300
PWRM is still available for $0.0375 cents a share and is continuing creeping closer to 30 RSI, which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.
PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover:
Processes - The manner in which the discoveries are made and tests developed
Discoveries - Protein disease footprints,
Products - Early detection tests, Biomarkers, and Drug Targets
The intellectual property that PWRM has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance:
Continue your research at www.power3medical.com
Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI)
Last: $6.72
Volume:250,909
Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI)recently announced that it has adjourned its Annual Meeting of Stockholders to 10:30a.m. Pacific Time, Thursday, July 1, 2010, which will be held at the Companys corporate office located at 157 Technology Drive, Irvine, California, 92618. The Companys proxy materials previously filed with the Securities and Exchange Commission on April 28, 2010, and first mailed to the Companys stockholders on or about May 17, 2010, and the proposal being submitted to a vote of the stockholders at the Annual Meeting, as described in such proxy materials, remain unchanged.
SPPI is a commercial-stage biotechnology company with a focus in oncology and hematology. The Companys strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. In addition to continuing to build an efficient in-house clinical research organization with regulatory and data management capabilities, the Company has established a commercial infrastructure to market its drug portfolio. The Company markets two oncology drugs, ZEVALIN and FUSILEV and has two drugs in late stage development, apaziquone and belinostat, along with a diverse pipeline. The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy.
For more information, please visit the Companys website at www.sppirx.com.
SIGA, SIGA Technologies, Inc.
Last: $3.95
Volume:385,021
SIGA, a bio-defense company, engages in the discovery, development, and commercialization of products for use in defense against biological warfare agents comprising smallpox and arenaviruses. It also involves in the discovery and development of other novel anti-infectives and antibiotics for the prevention and treatment of serious infectious diseases.
** SIGA reported the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246(R), SIGAs lead smallpox antiviral drug candidate. Analyses of the trials results are consistent with findings from previous studies of ST-246 and together show that the drug will likely be found to be a safe and well-tolerated therapeutic for the treatment of orthopoxvirus infections.
More about SIGA at www.siga.com
***********************************
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
***********************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.
by: Bill Pennyman
How The Revolutionary Virtual Ad Journal & E-Journal Are Reshaping Event Fundraising Techniques Kill Bill A Synopsis and its Cultural Context The Common Types of STDs and their Cures How to Deal with a Broken Heart – The Best Advice for a Broken Heart and How to Get Back on Your Feet How to Prepare Lumber & Stock for your wood projects? Learn Stock Trading - 5 Simple Ways to Understand Stock Trading Stock Pot - A Brief History Stock Trading System - How You could Make money From Them Tnnp And Eb5 Immigrant Investor Visas Compared Seasonal Beer Reviewed - Nosferatu Stock Ale You and Your Characteristics The Popular Sorts of STDs and their Cures Does James Connelly best penny stocks to buy works -How to find best one